Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naphazoline + chlorpheniramine + benzalkonium is a fixed-dose combination ophthalmic solution used for the temporary relief of symptoms associated with allergic conjunctivitis and eye irritation. **Naphazoline hydrochloride** is a sympathomimetic amine that acts as a potent vasoconstrictor by stimulating alpha-adrenergic receptors, thereby reducing ocular congestion and redness. **Chlorpheniramine maleate** is a first-generation alkylamine antihistamine that provides relief from allergic symptoms such as itching, watering, and puffiness by competitively antagonizing histamine H1 receptors. **Benzalkonium chloride** is a quaternary ammonium compound primarily included in the formulation as a preservative with antimicrobial properties, though it may also serve as an antiseptic in certain topical formulations. This combination is widely available as an over-the-counter (OTC) medication in various international markets, including India and Japan, to treat eye irritation caused by hay fever, pollen, and animal dander.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline + chlorpheniramine + benzalkonium.